Trials / Not Yet Recruiting
Not Yet RecruitingNCT06557213
a Cohort Study (Gut Microbiota and HCC)
Prediction of Liver Cancer Treatment Response Based on Gut Microbiota: a Cohort Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Xu Yong, MD · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To analyze the predictive role of intestinal microbiota in tyrosine kinase inhibitors (TKIs) combined with immunotherapy response in patients with intermediate and advanced liver cancer.
Detailed description
This is a prospective, observational cohort study. Patients with intermediate and advanced hepatocellular carcinoma who meet the enrollment and exclusion criteria are judged to be unresectable after evaluation by professional physicians, and are intended to be treated with anti-angiogenic targeted drugs combined with immune checkpoint inhibitors. During the treatment according to clinical needs, stool and blood samples were taken regularly, and the treatment response of patients was judged according to RECIST V1.1 criteria, and the common adverse reactions during treatment were evaluated by the CTCAE5.0 grading system, and the relationship between intestinal microbiota and liver cancer treatment response was analyzed.
Conditions
Timeline
- Start date
- 2024-08-30
- Primary completion
- 2026-05-20
- Completion
- 2026-11-20
- First posted
- 2024-08-16
- Last updated
- 2024-08-16
Source: ClinicalTrials.gov record NCT06557213. Inclusion in this directory is not an endorsement.